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Abstract
Approximately 5% to 10% of melanoma may be hereditary in nature, and about 2% of melanoma
can be specifically attributed to pathogenic germline mutations in cyclin-dependent kinase
inhibitor 2A (CDKN2A). To appropriately identify the small proportion of patients who benefit
most from referral to a genetics specialist for consideration of genetic testing for CDKN2A, we
have reviewed available published studies of CDKN2A mutation analysis in cohorts with invasive,
cutaneous melanoma and found variability in the rate of CDKN2A mutations based on geography,
ethnicity, and the type of study and eligibility criteria used. Except in regions of high melanoma
incidence, such as Australia, we found higher rates of CDKN2A positivity in individuals with 3 or
more primary invasive melanomas and/or families with at least one invasive melanoma and two or
more other diagnoses of invasive melanoma and/or pancreatic cancer among first- or second-
degree relatives on the same side of the family. The work summarized in this review should help
identify individuals who are appropriate candidates for referral for genetic consultation and
possible testing.
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BACKGROUND
It is estimated that 5% to 10% of all malignant melanomas occur in familial clusters1 and
work continues to identify all the genetic factors that play a role in melanoma risk and
optimal ways to use this information in treatment of the individual patient. There is
increasing awareness among health care professionals and the public about the inherited
basis of many cancers and the availability of genetic testing for relevant predisposing gene
mutations.2 Dermatologists and other health professionals should incorporate family history
and risk assessment into clinical practice to identify patients who may be at increased risk
for melanoma.
Germline mutations in cyclin-dependent kinase inhibitor 2A (CDKN2A) (INK4a) are
reported to be present in up to 40% of hereditary cases of melanoma, making it the most
significant high-risk melanoma susceptibility gene identified to date.3,4 Mutations in
CDKN2A are associated with increased risks for both melanoma and pancreatic cancer. By
age 80 years, an individual ascertained from multiple-case families with a CDKN2A
mutation has an increased risk of developing melanoma of 58% in Europe, 76% in the
United States, and 91% in Australia.5 Gene penetrance estimated by population-ascertained
mutation carriers is considerably lower, although still substantial (28% by age 80 years).6
The risk appears to vary between countries and families, and it is not yet clear whether this
variation results from the type of mutation, coinheritance with other genetic variations,
environmental exposures, or other not yet identified genetic variables. A correlation has
been established between the presence of a CDKN2A mutation and pancreatic cancer risk in
some families.7–19 Within families that demonstrated a predisposition to pancreatic cancer,
the relative risk for pancreatic cancer ranges from 9.4 (95% confidence interval 2.7–33.4)19
to 47.8 (95% confidence interval 28.4–74.7),20 or up to a 25% risk of developing pancreatic
cancer by age 80 years in a study of CDKN2A-positive families in the Netherlands.
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The classic family history features that raise the possibility of an inherited cancer syndrome
are multiple affected family members (particularly with a vertical pattern of inheritance),
occurrence of cancer types known to be associated with a specific hereditary syndrome,
individuals given the diagnosis of multiple primary cancers, and early age of onset. Here we
provide a review of the literature from 1994 to 2007 and an assessment of the predictive
value of these features to identify families that are likely to harbor a mutation in the
CDKN2A gene and would benefit from referral for genetic consultation and possibly testing.
Data in this review were summarized into tables and specified by country or region where
the study took place. Although we have attempted to synthesize these data into general
guidelines that are internationally applicable, the variability in incidence and penetrance of
CDKN2A mutations in different populations is such that clinicians must consider the
patient’s geographic region and genetic background when assessing individual patient risk.
There are no current relevant data on in situ melanomas and/or the lentigo maligna subtype
of in situ melanoma, and these should not be counted as a melanoma for purposes of genetic
risk assessment. Ocular melanomas are also not considered in this article.
Family history of melanoma
The likelihood of CDKN2A mutation detection increases with the number of melanomas in
the family (Table I; available online at www.eblue.org). Data from the two international
melanoma consortium studies, one a combined analysis of familial studies and the other a
cross-sectional survey of melanoma cases, indicate that the incidence of CDKN2A mutations
in families with only one melanoma is approximately 1% whereas the likelihood of mutation
detected in 2, 3, or 3 or more affected family members with melanoma are 4%, 8%, and
38%, respectively.4,6 The combined GenoMEL analysis and data in Table I (available online
at www.eblue.org) show that mutation detection rates are highly variable across regions.
Families with similar histories have a greater likelihood of harboring a mutation in lower
incidence countries. Importantly, mutation prevalence rates do not increase above 10% in
high incidence regions such as Australia until there are at least five cases of melanoma in the
family. In addition, mutations are more likely to be found in familial melanoma that has
been identified by clinic-based ascertainment than in similar families identified by
population-based ascertainment.
Multiple primary melanomas
Approximately 3% to 5% of all patients with melanoma will develop additional primary
melanomas in their lifetime.21 As with family history, the prevalence of CDKN2A mutations
increases with the number of primary melanoma diagnoses in the individual (Table II;
available online at www.eblue.org). Data from the Genes Environment and Melanoma Study
Group (GEM) indicate that the likelihood of a CDKN2A mutation in an individual with two
or more primary melanomas is 2%, but increases to 7% if additional family history is
present. The likelihood of mutation detection continues to increase with greater numbers of
primary melanomas. Studies of patients having ≥4 melanomas indicate a 29% to 100%
likelihood of mutation detection, at least in low incidence countries. Because of the impact
of family history on the likelihood of mutation detection, the data from studies of multiple
primary melanomas are subdivided in Table II (available online at www.eblue.org) by
whether or not additional family history has been excluded.
Melanoma and pancreatic cancer
GenoMEL data demonstrate that 28% of 178 families known to carry a CDKN2A mutation
also had one or more pancreatic cancers in the family.4 However, further analysis of these
data by geographic location shows that the CDKN2A mutation-positive families from
Australia do not have a significant association with pancreatic cancer, whereas there is an
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association in Europe and North America.3 Although it is not a feature of all CDKN2A
families, the presence of pancreatic cancer in a family with melanoma greatly increases the
likelihood of mutation detection (Table III; available online at www.eblue.org). A
GenoMEL analysis of families with 3 or more melanomas found CDKN2A mutations in
38%.4 However, if these families also had a pancreatic cancer diagnosis, the likelihood of a
mutation went up to 72%4 (Table III; available online at www.eblue.org). Data on
individuals presenting with double primaries (one melanoma, one pancreatic cancer) are
limited. Review of data from 5 separate studies looking at a combined total of 21 individuals
with double primaries found that 3 (15.0%) were found to have a CDKN2A mutation.
Despite the association of pancreatic cancer and CDKN2A, neither sporadic nor familial
pancreatic cancer appears to be a predictor of harboring a mutation. Studies of unselected
patients with pancreatic cancer who have no family history of melanoma or pancreatic
cancer indicate a 2% likelihood of mutation detection.13,22 These studies suggest that it is
the combination of both pancreatic cancer and melanoma that increases the likelihood of a
CDKN2A mutation, but that isolated pancreatic cancer and familial pancreatic cancer may
not (Table III; available online at www.eblue.org).
Age of melanoma diagnosis
A common feature of hereditary cancer syndromes is a younger age of diagnosis compared
with the mean age of diagnosis for that particular cancer in the general population. Table IV
(available online at www.eblue.org) compiles data on age of diagnosis of melanoma and
pancreatic cancer in CDKN2A mutation carriers. The mean age of melanoma diagnosis in
CDKN2A mutation carriers across the world is in the 30s to 40s, whereas the mean age in
high-risk melanoma families without CDKN2A mutations is in the 40s to 50s. In the United
States, the mean age of diagnosis of melanoma in known CDKN2A mutation carriers is 35
years (range 14–68 years)5 compared with a median age of 59 years in the general
population.23 There is a wide range in age of diagnosis of sporadic melanoma, with very
rare cases seen at younger than 10 years to older than 90 years.
Although younger onset is clearly a feature of CDKN2A mutations, in the absence of
additional family history, young onset of melanoma alone does not predict a high likelihood
of an identifiable mutation. Mutations are identified in less than 1% of individuals given the
diagnosis of melanoma when they are younger than 40 years (Table V; available online at
www.eblue.org).24–31 Overall, selection of patients based on young age of melanoma
diagnosis alone does not result in a sufficiently high likelihood of finding a mutation to
merit referral.
Clinically atypical nevi/dysplastic nevi
Some CDKN2A mutation-carrying families that exhibit numerous clinically atypical nevi
(CAN) (defined based on atypical clinical features alone) and dysplastic nevi (DN) resulting
in fulfillment of the formal criteria for familial atypical multiple mole melanoma
syndrome32 or atypical mole syndrome.33,34 Within melanoma-prone families, whether
CDKN2A-linked or not, the presence of CAN/DN is a strong risk factor for melanoma
development; however, some individuals who develop melanoma in this setting do not have
these markers.35 Furthermore, the association of CAN/DN with mutation carrier status in
known CDKN2A mutation families is complex, and many studies have indicated the nevus
phenotype to be a very unreliable indicator of CDKN2A mutation carrier status.36–40
CAN/DN is also seen outside melanoma-prone families either sporadically or genetically.
There have been limited studies to date examining germline CDKN2A mutation status in
patients with CAN. Celebi et al41 found no CDKN2A mutations in a study of 28 patients
with CAN and Ung-Juurlink42 found 8 mutations in 251 (3.2%) patients presenting with
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melanoma, CAN, or both. In this study, the phenotype of the mutation carriers was not
specified, but univariate analysis did not detect any relationship between CAN alone and
CDKN2A status. Matsumura et al43 found no mutations in 4 patients with nonfamilial CAN,
and de Snoo et al44 found 6 mutations in 167 (4%) patients with CAN, of whom 4 of the 6
turned out to have a positive family history for melanoma and one had 4 primary
melanomas.
In summary, CDKN2A genetic testing in patients with CAN/DN without a positive family
history of melanoma is not justified based on current data.
Other melanoma predisposition genes: Cyclin-dependent kinase 4, cyclin-dependent
kinase inhibitor 2A/p14 alternate reading frame, melanocortin 1 receptor
This article does not discuss the role of genetic testing for two other high-penetrance
melanoma predisposition genes, cyclin-dependent kinase 4 CDK4 or cyclin-dependent
kinase inhibitor 2A/p14 alternate reading frame CDKN2A/ARF.4 Risk estimates associated
with mutations in these genes have wider confidence intervals than those estimated for
CDKN2A mutations because so few have been reported. In patients who have a strong
family history and are negative for CDKN2A mutation, these tests could be considered but
are unlikely to be positive.
Melanocortin 1 receptor variants are associated with red hair and freckles. Melanocortin 1
receptor variants confer significant additional melanoma risk to CDKN2A mutation carriers
and further refinement of this risk is ongoing in many research laboratories.45,46
Melanocortin 1 receptor testing is currently available as a research investigation.
DISCUSSION
Candidate patients for clinical melanoma genetic assessment
Genetic testing is currently widely used for identifying individuals with hereditary colorectal
cancer and hereditary breast/ovarian cancer, but genetic testing of CDKN2A in the context of
melanoma is not part of routine practice. However, there are now at least 5 commercial
laboratories in the United States offering clinical CDKN2A testing,47 and there is growing
awareness by the lay public about the genetic basis of cancer and the availability of testing.
The objective of this article is to help clinicians identify individuals who are at significant
risk for harboring a genetic mutation and who could be referred to a genetic counseling
specialist.
We have summarized the predictive value of personal and family history of melanoma and
pancreatic cancer for identifying individuals who have an increased probability of harboring
a mutation in the CDKN2A gene. The likelihood of detecting a CDKN2A mutation depends
greatly on the population being studied, which may be a result of differences in penetrance
associated with variation in melanoma predisposing phenotype (eg, fair skin, red hair) and
the local amount/intensity of ultraviolet radiation exposure. In geographic areas with higher
background rates of melanoma, there is greater likelihood of having multiple family
members with melanoma or multiple primary melanomas caused by reasons other than a
CDKN2A mutation. However, melanoma penetrance in CDKN2A mutation carriers is also
higher in areas with high background rates of melanoma, indicating a potential interaction
between CDKN2A and the other predisposing factors for melanoma in these areas.
The variability in the background incidence of melanoma and penetrance of CDKN2A
mutations between countries is such that there is no single guideline for genetic testing that
would be appropriate to apply worldwide. We, therefore, provide a framework that
clinicians can use to identify appropriate candidates for genetic evaluation with regard to the
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specific populations they serve. For moderate to high melanoma incident areas, individuals
with 3 or more primary melanomas and/or families with at least one invasive melanoma and
two or more other diagnoses of melanoma and/or pancreatic cancer in aggregate among
first- or second-degree relatives on the same side of the family are appropriate candidates for
a genetics evaluation (Table VI; available online at www.eblue.org). For low melanoma
incidence areas, two melanoma and/or pancreatic cancer events in a family may be sufficient
to consider a genetics referral (Table VI; available online at www.eblue.org). There are
insufficient data at this time to specifically determine the likelihood of mutation detection in
individuals presenting with synchronous or metachronous diagnoses of melanoma and
pancreatic cancer. However, this is another group that may warrant referral for genetics
evaluation.
There are important considerations regarding the clinical use and potential implications of
CDKN2A genetic testing. Before undergoing genetic testing, patients should be informed of
the potential benefits and limitations of testing by a genetic counselor or other professional
with expertise in melanoma genetics (Table VII; available online at www.eblue.org).48 To
date there are limited data regarding the implications of CDKN2A genetic testing. Aspinwall
et al49 found an increase in screening and precautionary behaviors among both mutation-
positive and mutation-negative patients. After receiving test results, 55% reported adopting
at least one screening behavior. Long-term follow-up data are needed to determine whether
these behavioral changes are maintained, but data from testing of other hereditary cancer
syndromes indicate that noncarriers in a mutation-positive family are likely to continue to
undergo risk-appropriate screening.50,51 Therefore, it is important that genetic testing be
done in the context of counseling and education.
Regardless of whether or not genetic testing is part of the care for families with hereditary
melanoma, there is likely benefit from identifying these highest risk families and targeting
them for intensive screening and education.
SUMMARY
The higher rates of CDKN2A mutation positivity in individuals with 3 or more primary
melanomas and/or families with at least one melanoma and two or more other diagnoses of
melanoma and/or pancreatic cancer in aggregate among first- or second-degree relatives on
the same side of the family warrant referral for a genetics evaluation. Use of these guidelines
would increase the proportion of individuals identified at high risk and referred
appropriately to genetic services. Patients at high risk should be allowed to weigh the pros
and cons of testing and will–irrespective of actually being testing–benefit from tailored
education and screening.
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Table I
Percentage of cyclin-dependent kinase inhibitor 2A mutations increases with number of melanoma diagnoses
in the family
No. of
individuals
with
melanoma
in family* Study Study location
Degree of
relationship†
Families
positive for
CDKN2A mutation
1 Begg et al,6 2005 Population
based
GEM: North America (British Columbia,
Ontario, California, Michigan, New Jersey,
and North Carolina)
n/a 24/1727 (1%)
Begg et al,6 2005 Population
based
GEM: Australia (New South Wales and
Tasmania)
n/a 13/1109 (1%)
Begg et al,6 2005 Population
based
GEM: United States (California, Michigan,
New Jersey, North Carolina), Australia (New
South Wales, Tasmania), Canada (British
Columbia, Ontario), Italy (Turin)
n/a 39/2996 (1%)
1 or 2 Vasen et al,8 2000‡ Netherlands nd 4/8 (50%)
Lamperska et al,52 2002 Poland nd 0/16 (0%)
2 Fitzgerald et al,53 1996 United States (Massachusetts) 1, 2 3/24 (13%)
MacKie et al,54 1998 United Kingdom (Scotland) nd 4/14 (29%)
Soufir et al,55 1998 France nd 8/28 (29%)
Holland et al,56 1999 Australia nd 1/65 (2%)
Newton-Bishop et al,57 1999/
Harland et al,58 1997
United Kingdom (England and Wales) nd 1/22 (4%)
Ruiz et al,59 1999 Spain 1, 2 2/18 (11%)
Tsao et al,29 2000 United States (Massachusetts) 1, 2, 3 0/12 (0%)
Yakobson et al,60 2000 Israel 1, 2, 3 2/24 (8%)
Della Torre et al,61 2001‡ Italy nd 2/8 (25%)
Alao et al,62 2002 United Kingdom (London) 1 1/12 (8%)
Mantelli et al,63 2002‡ Italy 1 11/47 (23%)
Chaudru et al,64 2004 France nd 7/34 (21%)
Debniak et al,65 2004 Poland nd 0/12 (0%)
Landi et al,66 2004 Italy (South, Central, North, Sardinia,1 family
from Russia)
nd 3/42 (7%)
Soufir et al,25 2004 France 1, 2 1/16 (6%)
Begg et al,6 2005 Population
based
GEM: North America (British Columbia,
Ontario, California, Michigan, New Jersey,
and North Carolina)
1 11/236 (5%)
Begg et al,6 2005 Population
based
GEM: Australia (New South Wales and
Tasmania)
1 7/221 (3%)
Begg et al,6 2005 Population
based
GEM: United States (California, Michigan,
New Jersey, North Carolina), Australia (New
South Wales, Tasmania), Canada (British
Columbia, Ontario), Italy (Turin)
1 19/463 (4%)
Lang et al,67 2005 United Kingdom (Scotland) nd 4/28 (14%)
Marian et al,68 2005 Israel nd 0/7 (0%)
Eliason et al,69 2006 United States (Utah) 1, 2 1/36 (3%)
J Am Acad Dermatol. Author manuscript; available in PMC 2012 March 19.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Leachman et al. Page 14
No. of
individuals
with
melanoma
in family* Study Study location
Degree of
relationship†
Families
positive for
CDKN2A mutation
Hocevar et al,70 2006 Slovenia 1, 2 3/8 (38%)
Huber and Ramos,71 2006 Brazil 1, 2 1/10 (10%)
Niendorf et al,72 2006 United States (Massachusetts) 1 5/76 (7%)
≥2 Kamb et al,73 1994 United States (7 Utah, 1 Texas), Netherlands nd 2/13 (15%)
Platz et al,74 1997 Sweden 1, 2, 3 5/100 (5%)
Fargnoli et al,75 1998 Italy, Austria 1, 2 4/10 (40%)
Liu et al,76 1999 Canada (Toronto) nd 23/82 (28%)
Borg et al,11 2000‡ Sweden 1, 2 10/52 (19%)
Mantelli et al,77 2004‡ Italy 1 9/34 (26%)
Marian et al,68 2005 Israel nd 0/13 (0%)
Casula et al,78 2007 Italy (South Italy and Sardinia) nd 5/29 (17%)
3 Flores et al,79 1997 Australia nd 1/19 (5%)
MacKie et al,54 1998 United Kingdom (Scotland) nd 1/1 (100%)
Holland et al,56 1999 Australia nd 4/38 (11%)
Newton-Bishop et al,57 1999 United Kingdom (England and Wales) nd 1/7 (14%)
Yakobson et al,60 2000 Israel 1, 2, 3 0/5 (0%)
Della Torre et al,61 2001‡ Italy nd 0/2 (0%)
Alao et al,62 2002 United Kingdom (London) 1, 2 0/1 (0%)
Mantelli et al,63 2002‡ Italy nd 6/11 (55%)
Debniak et al,65 2004 Poland nd 0/3 (0%)
Landi et al,66 2004 Italy (South, Central, North, Sardinia,1 family
from Russia)
nd 0/11 (0%)
Soufir et al,25 2004 France 1, 2 1/5 (20%)
Begg et al,6 2005 Population
based
GEM: North America (British Columbia,
Ontario, California, Michigan, New Jersey,
and North Carolina)
1 4/38 (11%)
Begg et al,6 2005 Population
based
GEM: Australia (New South Wales and
Tasmania)
1 2/35 (6%)
Begg et al,6 2005 Population
based
GEM: United States (California, Michigan,
New Jersey, North Carolina), Australia (New
South Wales, Tasmania), Canada (British
Columbia, Ontario), Italy (Turin)
1 6/73 (8.2%)
Lang et al,67 2005 United Kingdom (Scotland) nd 2/3 (67%)
Eliason et al,69 2006 United States (Utah) 1, 2 1/18 (7%)
Hocevar et al,70 2006 Slovenia 1, 2 2/3 (67%)
Huber and Ramos,71 2006 Brazil 1, 2 1/2 (50%)
Niendorf et al,72 2006 United States (Massachusetts) nd 2/23 (9%)
≥3 Fitzgerald et al,53 1996 United States (Massachusetts) 1, 2 2/4 (50%)
Soufir et al,55 1998 France nd 13/20 (65%)
Ruiz et al,59 1999 Spain 1, 2 3/9 (33%)
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No. of
individuals
with
melanoma
in family* Study Study location
Degree of
relationship†
Families
positive for
CDKN2A mutation
Tsao et al,29 2000 United States (Massachusetts) 1, 2, 3 1/2 (50%)
Vasen et al,8 2000‡ Netherlands nd 15/19 (79%)
Chaudru et al,64 2004 France nd 13/19 (68%)
Goldstein et al,4 2006 GenoMEL nd 178/466 (38%)
≥4 Flores et al,79 1997 Australia nd 9/29 (31%)
MacKie et al,54 1998 United Kingdom (Scotland) nd 1/1 (100%)
Holland et al,56 1999 Australia nd 6/28 (21%)
Newton-Bishop et al,57 1999 United Kingdom (England and Wales) nd 7/13 (54%)
Yakobson et al,60 2000 Israel 1, 2, 3 0/1 (0%)
Della Torre et al,61 2001‡ Italy nd 3/4 (75%)
Mantelli et al,63 2002‡ Italy nd 4/4 (100%)
Debniak et al,65 2004 Poland nd 0/1 (0%)
Landi et al,66 2004 Italy (South, Central, North, Sardinia,1 family
from Russia)
nd 1/2 (50%)
Soufir et al,25 2004 France 1, 2 1/2 (50%)
Begg et al,6 2005 Population
based
GEM: North America (British Columbia,
Ontario, California, Michigan, New Jersey,
and North Carolina)
1 1/6 (17%)
Begg et al,6 2005 Population
based
GEM: Australia (New South Wales and
Tasmania)
1 0/12 (0%)
Begg et al,6 2005 Population
based
GEM: United States (California, Michigan,
New Jersey, North Carolina), Australia (New
South Wales, Tasmania), Canada (British
Columbia, Ontario), Italy (Turin)
1 1/18 (6%)
Lang et al,67 2005 United Kingdom (Scotland) nd 1/1 (100%)
Eliason et al,69 2006 United States (Utah) 1, 2 3/6 (50%)
Huber and Ramos,71 2006 Brazil 1, 2 0/1 (0%)
Niendorf et al,72 2006 United States (Massachusetts) nd 6/18 (33%)
Unknown Aitken et al,80 1999 Australia (Queensland) nd 9/87 (10%)
CDKN2A, Cyclin-dependent kinase inhibitor 2A; n/a, not applicable; nd, not discussed.
Bolded studies reflect large consortium-based data sets.
*
Families may have included individuals with multiple primary melanoma (MPM). Specific information on MPM can be found in Table II.
†
1 = First degree, 2 = second degree, 3 = third degree.
‡
Population in which common mutation accounts for majority of CDKN2A mutations identified.
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Table II
Percentage of cyclin-dependent kinase inhibitor 2A mutations increases with number of primary melanomas
No. of
primaries Study Study location
Family
history*
Cases positive for
CDKN2A mutation
2 MacKie et al,54 1998† United Kingdom (Scotland) 1/14 (7%)
Monzon et al,81 1998 Canada (Toronto) and United States (Maryland) ✓ 3/25 (8%)
Hashemi et al,82 2000† Sweden ✓ 3/61 (5%)
Auroy et al,83 2001† France 6/85 (7%)
Blackwood et al,84 2002 United States (Pennsylvania) ✓ 5/72 (7%)
Peris et al,85 2004 Europe (Germany, Italy, and Austria) 1/8 (13%)
Soufir et al,25 2004 France 0/14 (0%)
Puig et al,86 2005 Spain ✓ 8/81 (10%)
Eliason et al,69 2006 United States (Utah) ✓✓ 1/6 (17%)
≥2 Harland et al,58 1997 United Kingdom 0/3 (0%)
MacKie et al,54 1998† United Kingdom (Scotland) 2/17 (12%)
✓✓ 5/5 (100%)
Soufir et al,55 1998 France (1 family living in Italy) ✓✓ 16/20 (80%)
Holland et al,56 1999 Australia ✓✓ 6/28 (21%)
Liu et al,76 1999 Canada (Toronto) and United States (Maryland) ✓ 5/33 (15%)
Newton-Bishop et al,57 1999 United Kingdom (England and Wales) ✓✓ 6/20 (30%)
Ruiz et al,59 1999 Spain 1/8 (13%)
Hashemi et al,82 2000† Sweden 2/65 (3%)
✓ 7/15 (47%)
Yakobson et al,60 2000 Israel 0/2 (0%)
✓ 1/1 (100%)
Auroy et al,83 2001† France 9/100 (9%)
Alao et al,62 2002 United Kingdom 0/4 (0%)
✓ 1/1 (100%)
Blackwood et al,84 2002 United States (Pennsylvania) ✓ 5/44 (11%)
Mantelli et al,63 2002† Italy (Liguria) ✓✓ 11/23 (48%)
Landi et al,66 2004 Italy (South, Central, North, Sardinia, 1 family from
Russia)
✓✓ 2/15 (13%)
Mantelli et al,77 2004† Italy (Liguria) 4/14 (21%)
Nielsen et al,87 2004† Sweden (South) nd 3/15 (20%)
Peris et al,85 2004 Europe (Germany, Italy, Austria) 3/14 (21%)
Rutter et al,88 2004 United States (Pennsylvania and California) ✓ 1/22 (5%)
Begg et al,6 2005 Population based GEM: United States (California, Michigan, New
Jersey, North Carolina), Australia (New South
Wales, Tasmania), Canada (British Columbia,
Ontario), Italy (Turin)
✓
17/946 (2%)
19/263 (7%)
Lang et al,67 2005 United Kingdom (Scotland) ✓✓ 3/5 (60%)
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No. of
primaries Study Study location
Family
history*
Cases positive for
CDKN2A mutation
Marian et al,68 2005 Israel nd 0/5 (0%)
Nagore et al,27 2005 Spain ✓ 1/3 (33%)
Puig et al,86 2005 Spain 6/73 (8%)
✓ 11/31 (36%)
Casula et al,78 2007 Italy (South Italy and Sardinia) ✓ 5/34 (15%)
Goldstein et al,4 2006 GenoMEL: North America and Europe ✓✓ 97/129 (75%)
Hocevar et al,70 2006 Slovenia ✓✓ 5/6 (83%)
Stratigos et al,30 2006 Greece (Athens) 2/2 (100%)
3 MacKie et al,54 1998† United Kingdom (Scotland) 0/2 (0%)
Monzon et al,81 1998 Canada (Toronto) and United States (Maryland) 1/5 (20%)
Hashemi et al,82 2000† Sweden ✓ 4/12 (33%)
Auroy et al,83 2001† France 0/9 (0%)
Blackwood et al,84 2002 United States (Pennsylvania) ✓ 1/14 (7%)
Peris et al,85 2004 Europe (Germany, Italy, Austria) 0/2 (0%)
Soufir et al,25 2004 France 0/3 (0%)
Puig et al,86 2005 Spain ✓ 4/14 (29%)
≥3 Eliason et al,69 2006 United States (Utah) ✓✓ 3/3 (100%)
Niendorf et al,72 2006 United States (Massachusetts) 0/6 (0%)
≥4 MacKie et al,54 1998† United Kingdom (Scotland) 1/1 (100%)
Monzon et al,81 1998 Canada (Toronto) and United States (Maryland) 1/3 (33%)
Hashemi et al,82 2000† Sweden ✓ 2/7 (29%)
Auroy et al,83 2001† France 3/6 (50%)
Blackwood et al,84 2002 United States (Pennsylvania) ✓ 3/9 (33%)
Peris et al,85 2004 Europe (Germany, Italy, and Austria) 2/4 (50%)
Puig et al,86 2005 Spain ✓ 5/9 (56%)
CDKN2A, Cyclin-dependent kinase inhibitor 2A; nd, not discussed.
Bolded studies reflect large consortium-based data sets.
*
Blank = no family history of melanoma;
✓
ascertained multiple primary cases regardless of family history;
✓✓
ascertained by family history consistent with a melanoma-prone family.
†
Population in which common mutation accounts for majority of CDKN2A mutations identified.
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Table III
Percentage of cyclin-dependent kinase inhibitor 2A mutations in families with pancreatic cancer increases
when 3 or more cancer events are present
No. of cancer
events
(pancreatic
cancer
with/without
melanoma) in
individual or
family Description Study Study location
Families positive
for CDKN2A
mutation
1 Pa ca in individual Ghiorzo et al,13 2004 Italy (Liguria)  1/47* (2%)
Ghiorzo et al,22 2007 Italy (Liguria)  1/63* (2%)
Pa ca in individual aged ≤ 50 y Lal et al,15 2000 Canada (Toronto)   0/10 (0%)
Pa ca and nonmelanoma cancer in individual Gerdes et al,89 2000 Germany (Marburg) 1†/14 (7%)
2 Pa ca and melanoma in individual Lal et al,16 2000 Canada (Toronto)   2/14 (14%)
Lal et al,15 2000 Canada (Toronto)     0/1 (0%)
Austin et al,90 2003 United States (various)     0/2 (0%)
Ghiorzo et al,13 2004 Italy (Liguria)     0/2 (0%)
Soufir et al,25 2004 France     1/1 (100%)
Ghiorzo et al,22 2007 Italy (Liguria)     1/1 (100%)
1 Pa ca and 1 melanoma in family Lal et al,15 2000 Canada (Toronto)     0/2 (0%)
Bartsch et al,12 2002 Germany     2/4 (50%)
Prowse et al,91 2003 United States (Philadelphia)     0/2 (0%)
Ghiorzo et al,13 2004 Italy (Liguria)     1/1 (100%)
2 Pa ca in family Lal et al,15 2000 Canada (Toronto)   0/12 (0%)
Bartsch et al,12 2002 Germany   0/13 (0%)
Ghiorzo et al,22 2007 Italy (Liguria)     1/7 (14%)
≥ 2 1 Pa ca and ≥ 1 melanoma in family Austin et al,90 2003 United States (various)     0/4 (0%)
≥ 2 Pa ca in family Moskaluk et al,92 1998 United States (various)   0/20 (0%)
Austin et al,90 2003 United States (various)     0/6 (0%)
≥ 3 1 Pa ca and ≥ 2 melanoma in family Lal et al,15 2000 Canada (Toronto)     1/1 (100%)
Landi et al,66 2004 Italy     2/3 (67%)
1 Pa ca and ≥ 3 melanoma in family Bartsch et al,12 2002 Germany     0/1 (0%)
Prowse et al,91 2003 United States (Philadelphia)     1/1 (100%)
Goldstein et al,4 2006 GenoMEL 31/43 (72%)
≥ 1 Pa ca and ≥ 2 melanoma in family Soufir et al,55 1998 France (1 in Italy)     4/9 (44%)
Mantelli et al,63 2002 Italy (northern, central)     6/9 (67%)
Lang et al,67 2005 United Kingdom (Scotland)     0/2 (0%)
2 Pa ca and 1 melanoma in family Moskaluk et al,92 1998 United States (various)     1/1 (100%)
Ghiorzo et al,22 2007 Italy (Liguria)     1/1 (100%)
≥ 2 Pa ca and ≥ 3 melanoma Goldstein et al,4 2006 GenoMEL 13/16 (81%)
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No. of cancer
events
(pancreatic
cancer
with/without
melanoma) in
individual or
family Description Study Study location
Families positive
for CDKN2A
mutation
Member of pa ca registry with FAMMM
cutaneous phenotype
Lynch et al,18 2002 United States (Creighton)     8/8 (100%)
≥ 3 Pa ca in family Lal et al,15 2000 Canada (Toronto)     0/4 (0%)
Bartsch et al,12 2002 Germany     0/5 (0%)
CDKN2A, Cyclin-dependent kinase inhibitor 2A; FAMMM, familial atypical multiple mole melanoma; Pa ca, pancreatic cancer.
Bolded studies reflect large consortium-based data sets.
*
Complete family history not provided on all cases.
†
Mutation carrier had cancer of pancreas, thyroid, vocal cord, and basal cell. No family history of cancer was present.
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Table IV
Age of diagnosis of melanoma and pancreatic cancer in individuals with cyclin-dependent kinase inhibitor 2A
mutations
Study Study location
High-risk CDKN2A negative
family
(range), y*
CDKN2A positive family
(range), y
Melanoma
     Burden et al,93 1999† United Kingdom (Scotland) 51 mean 37 mean
     Ghiorzo et al,94 1999 Italy (Liguria) 47 median 48 median‡
     Goldstein et al,95 2000 United States (various) nd 34.2 median§
     Hashemi et al,82 2000‡ Sweden 54 median 42 median
     Vasen et al,8 2000† Netherlands 44 (12–71) mean 39 (15–72) mean
     Auroy et al,83 2001 France 44.1 (17–75) mean 43.9 (28–60) mean
     Bish op et al,5 2002 GenoMEL nd 37.5 (12–86) mean
     Blackwood et al,84 2002 United States (Pennsylvania) 50 mean 39.7 mean
     Mantelli et al,63 2002† Italy (northern and central) 48 median 42 median
     Rulyak et al,10 2003 United States (various) nd 51 median
     Ghiorzo et al,13 2004† Italy (Liguria) 49.4 mean 46.5 mean
     Mantelli et al,77 2004† Italy (Liguria) 47 median 41 median
     Lang et al,67 2005 United Kingdom (Scotland) 46 mean 35 mean
     Puig et al,86 2005 Spain 45.8 (± 16.1) mean 32.9 (± 12.6) mean
     Gold stein et al,4 2006 GenoMEL 45 median 36 median
     Niendorf et al,72 2006 United States (Massachusetts) 44.4 (95% CI 42.0–46.9) mean 33.2 (95% CI 25.9–40.5)
mean
Pancreas
     Vasen et al,8 2000† Netherlands nd 58 (38–77) mean
     de Vos tot Nederveen Cappel et al,96
2003†
Netherlands nd 58 (43–74) mean
     Rulyak et al,10 2003 United States (various) nd 59 median
CDKN2A, Cyclin-dependent kinase inhibitor 2A; CI, confidence interval; nd, not discussed.
Bolded studies reflect large consortium-based data sets.
*
CDKN2A negative families fulfilled the same eligibility criteria as CDKN2A positive families; study dependent.
†
Population in which common mutation accounts for majority of CDKN2A mutations identified.
‡
Median age of diagnosis in general population was 60 y.
§
Median age of diagnosis in general population was 54 y.
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Table VI
Candidacy for consideration of genetic testing
Low melanoma incidence area/population Moderate to high melanoma incidence area/population
• Two (synchronous or metachronous) primary melanomas in an
individual and/or
• Three (synchronous or metachronous) primary melanomas in an
individual and/or
• Families with at least one invasive melanoma and one or more
other diagnoses of melanoma and/or pancreatic cancers among first-
or second-degree relatives on the same side of the family
• Families with at least one invasive melanoma and two or more other
diagnoses of invasive melanoma and/or pancreatic cancer among first-
or second-degree relatives on the same side of the family
This table refers to pathologically confirmed invasive melanoma.
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Table VII
Resources for finding genetic services and research opportunities
National Society of Genetic Counselors http://www.nsgc.org Find local cancer genetics resources
National Cancer Institute Cancer
Genetics Service Directory
http://www.cancer.gov/search/geneticsservices/ Find local cancer genetics resources
GenoMEL: international melanoma
genetics research consortium
http://www.genomel.org/ Information about familial melanoma and
research opportunities
GeneTests http://www.genetests.org Find laboratories offering clinical genetic testing
services
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